Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2017 Oct 26.

Published in final edited form as: Leukemia. 2017 Apr 25;31(12):2791–2798. doi: 10.1038/leu.2017.120

Table 2.

Adverse Events At Least Possibly Related, all grades, by dose level

Body System	Stage I																	Stage II
Body System	DL1		DL 2			DL 3			DL 4		DL 5			DL 6^*				DL 1			DL 2			DL 3
Grade	1	2	1	2	3	1	2	3	1	2	1	2	3	1	2	3	4	1	2	3	1	2	3	1	2	3
Hematology	0	2	0	1	1	0	0	2	1	1	0	0	1	0	1	2	3	0	1	0	0	0	0	0	0	2
Pulmonary	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Coagulation	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Constitutional	1	0	2	0	0	0	0	0	0	0	1	0	0	2	3	0	0	1	0	0	0	0	0	1	0	0
Dermatology/Skin	1	0	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	1	0	0	0	0	0
Gastrointestinal	0	0	0	1	0	0	1	0	0	0	2	0	0	1	3	0	0	0	0	0	2	0	0	0	1	0
Hepatic	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Endocrine	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
Infection/FN	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Ocular/Vision	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Pain	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0
Syndromes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	0
Cardiovascular	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	0	0	0	0	0	0	1

^*

Recommended phase 2 dose